Patient survey on cancer genomic medicine in Japan under the national health insurance system
Hidenori Kage,Nana Akiyama,Hyangri Chang,Aya Shinozaki‐Ushiku,Mirei Ka,Junichi Kawata,Manabu Muto,Yusuke Okuma,Natsuko Okita,Katsuya Tsuchihara,Junko Kikuchi,Hidekazu Shirota,Hideyuki Hayashi,Toshio Kokuryo,Shinichi Yachida,Akira Hirasawa,Makoto Kubo,Hirotsugu Kenmotsu,Masahiko Tanabe,Tetsuo Ushiku,Kaori Muto,Yasuyuki Seto,Katsutoshi Oda
DOI: https://doi.org/10.1111/cas.16065
IF: 5.7
2024-01-27
Cancer Science
Abstract:In Japan, where comprehensive genomic profiling tests are given as part of the national healthcare system, patient satisfaction of the test process was high. More patients need to be treated with genomically matched therapy. In Japan, comprehensive genomic profiling (CGP) tests have been reimbursed under the national health care system for solid cancer patients who have finished standard treatment. More than 50,000 patients have taken the test since June 2019. We performed a nation‐wide questionnaire survey between March 2021 and July 2022. Questionnaires were sent to 80 designated Cancer Genomic Medicine Hospitals. Of the 933 responses received, 370 (39.7%) were web based and 563 (60.3%) were paper based. Most patients (784, 84%) first learned about CGP tests from healthcare professionals, and 775 (83.1%) gave informed consent to their treating physician. At the time of informed consent, they were most worried about test results not leading to novel treatment (536, 57.4%). On a scale of 0–10, 702 respondents (75.2%) felt that the explanations of the test result were easy to understand (7 or higher). Ninety‐one patients (9.8%) started their recommended treatment. Many patients could not receive recommended treatment because no approved drugs or clinical trials were available (102/177, 57.6%). Ninety‐eight patients (10.5%) did not wish their findings to be disclosed. Overall satisfaction with the CGP test process was high, with 602 respondents (64.5%) giving a score of 7–10. The major reason for choosing 0–6 was that the CGP test result did not lead to new treatment (217/277, 78.3%). In conclusion, satisfaction with the CGP test process was high. Patients and family members need better access to information. More patients need to be treated with genomically matched therapy.
oncology